Baxter BioScience to acquire cancer drugs from Sigma-Tau Finanziaria for $900m
Oncaspar (pegaspargase), an investigational biologic calaspargase pegol, is one of the acquired drugs and transaction related to this drug is expected to be completed in the third quarter
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.